Abstract: OBJECTIVE To evaluate the clinical efficacy of reduced glutathione(GSH) and magnesium isoglycyrrhizinate (YGC) in abnormal liver enzymes caused by infectious mononucleosis(IM) in children. METHODS Through retrospective study, 171 cases of IM children in five years were distributed into GSH group, YGC group and combination group. Firstly, background balance of each group was analyzed, disease recovery among three groups was investigated. Secondly, liver enzyme indexes before and after medication were compared. In the end, the single factor which had significant differences was included into multiple linear regression analysis, and factors within a same group influencing protection effect of hepatic protectant for liver enzyme abnormality were evaluated. RESULTS There was no significant difference in the recovery rate of three groups in the treatment of liver enzyme abnormality, but YGC group had alanine aminotransferase(ALT) level significantly lower than that of combination group, and abnormal lymphocyte(AL) level significantly lower than that of the GSH group(P<0.05). In addition, multiple linear regression analysis of the GSH group showed that weight and medication duration had statistical significance in the decreasing of liver enzyme ALT(P<0.05). CONCLUSION The 3-5 mg·kg^-1 of YGC, a commonly used clinical dose, improve mild and moderate liver enzyme abnormality caused by IM in children significantly. The degree of GSH reduce liver enzyme abnormality may be related to body weight and medication duration.